Consistently, deletion of miR-148a or miR-152 binding regions in 3UTR of IRS-1 did not exert the effect of miR-148a or miR-152 overexpression on inhibition of cell proliferation, indicating that these miRNAs affect cancer cell proliferation via IRS-1 suppression
That CagriSema is approved, or approvable, anywhere as of mid-2026 it is investigational, with its benefitrisk profile still under regulatory review
and promote blood vessel formation
[DOI] [PMC free article] [PubMed] [Google Scholar] 23
The studies also highlight: - Early statin initiation in type 2 diabetes lowers CVD and allcause mortality across risk levels - No increase in cancer risk with longterm statin use - A need for closer monitoring for myasthenia gravis in the first treatment year, especially at higher doses Together, these findings strengthen the case for individualised, evidencebased statin therapy in clinical practice
I guess Jimmy Carr is non-secretor